Perspective Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

CATX$0.86+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

Perspective Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Operations

(Dollars and shares in thousands, except for per share amounts)

Year ended December 31, · Six months ended December 31, · Year ended June 30,
2023 · 2022 · 2022
Grant revenue	$1,434	$	-	$	-
Gross profit	1,434		-		-
Operating expenses:
Research and development	21,311		468		850
General and administrative	21,064		4,848		5,569
Loss on disposal of property and equipment	-		305		-
Total operating expenses	42,375		5,621		6,419
Operating loss	(40,941)		(5,621)		(6,419)
Non-operating income:
Interest income	934		561		119
Interest expense	(84)		-		-
Other income	2		-		-
Equity in loss of affiliate	(17)		-		-
Total non-operating income	835		561		119
Net loss from continuing operations	(40,106)		(5,060)		(6,300)
Net loss from discontinued operations	(9,053)		(2,275)		(972)
Net loss before income taxes	(49,159)		(7,335)		(7,272)
Deferred income tax benefit	2,651		-		-
Net loss	$(46,508)		$(7,335)		$(7,272)
Basic and diluted loss per share:
Loss from continuing operations	$(0.14)		$(0.04)		$(0.04)
Loss from discontinued operations	(0.03)		(0.01)		(0.01)
Basic and diluted loss per share	$(0.17)		$(0.05)		$(0.05)
Weighted average shares used in computing net loss per share:
Basic and diluted	267,643		142,103		141,987

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.